Skip to main content
. 2017 Jul 25;19(9):661–671. doi: 10.1016/j.neo.2017.06.001

Figure 1.

Figure 1

Synergy screening identifies combinatorial benefit between IMGN529 and anti-CD20 antibodies, which requires the intact ADC. (A) Heat map of synergy values for IMGN529 in combination with anti-CD20 antibodies. The cell line panel included ABC DLBCL (green), GCB DLBCL (orange), MCL (blue), and BL (gray) lines. (B) Synergy scores for rituximab in combination with the K7153A antibody, free DM1, or intact IMGN529 evaluated in U-2932, DOHH-2, and OCI-Ly18 cells.